Dr. Rogers discusses FDA approval of InterStim X system

The device is indicated for overactive bladder, chronic fecal incontinence, and non-obstructive urinary retention.

Related Videos

Related Content

Advertisement

March 4th 2025

FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI

Hannah Clarke

The ARID II trial is assessing the safety and effectiveness of the device in men who are scheduled to undergo robotic-assisted radical prostatectomy.

March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

February 11th 2025

Survey data highlights substantial impact of postpartum incontinence

Hannah Clarke

Overall, 85% of respondents indicated they experienced frequent bladder leaks.

March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke

Functional success was achieved in 58% of patients at 5-year follow-up.

January 7th 2025

Sunobinop shows promise in phase 1b trial for overactive bladder

Hannah Clarke

Sunobinop resulted in a reduction in urinary urgency, urinary frequency, and incontinence episodes over the treatment period compared with placebo.

Related Content

Advertisement

March 4th 2025

FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI

Hannah Clarke

The ARID II trial is assessing the safety and effectiveness of the device in men who are scheduled to undergo robotic-assisted radical prostatectomy.

March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

February 11th 2025

Survey data highlights substantial impact of postpartum incontinence

Hannah Clarke

Overall, 85% of respondents indicated they experienced frequent bladder leaks.

March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke

Functional success was achieved in 58% of patients at 5-year follow-up.

January 7th 2025

Sunobinop shows promise in phase 1b trial for overactive bladder

Hannah Clarke

Sunobinop resulted in a reduction in urinary urgency, urinary frequency, and incontinence episodes over the treatment period compared with placebo.